AMGEN Inc
NASDAQ: AMGN
$280.01
-$13.99 (-4.8%)
Closing Price on November 26, 2024
AMGN Articles
Finally, concerns about biotech seem to be waning. An RBC research report notes that at the recent political conventions there was little to no mention of drug pricing.
Published:
Last Updated:
Amgen is expected to report its second-quarter financial results after the markets close on Wednesday. Will it go the same way as Gilead Sciences did earlier this week?
Published:
Last Updated:
The short interest data are out for the July 15 settlement date. Short interest increased across many of these selected biotech stocks.
Published:
Last Updated:
24/7 Wall St. has put together a preview of Alphabet, Amazon.com, Facebook and some of the other major companies reporting their quarterly results this week.
Published:
Last Updated:
The June 30 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
Published:
Last Updated:
Credit Suisse has taken a look at which biotech companies in its coverage have the least credit given to pipeline potential at current levels.
Published:
Last Updated:
Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health care if...
Published:
Last Updated:
The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. After all, a cure or...
Published:
Last Updated:
The May 31 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
Published:
Last Updated:
The May 13 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
Published:
Last Updated:
The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these selected biotech stocks.
Published:
Last Updated:
One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the position that Medivation found itself in.
Published:
Last Updated:
With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls by the week's end.
Published:
Last Updated:
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated: